Fig. 1: Study design outlining longitudinal immunization of mRNA BNT162b2 across the lifespan.
From: mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
Schematic representation of the study design showing three mouse age groups (a) and treatments within each age group (b). Three- and 11-month-old BALB/c mice were included in the study at week 0 and received the following treatments: mock PBS injection (naive); primary mRNA vaccination series at weeks 32–34 (recent vax); primary vaccination series at weeks 0–2 (distant vax); and primary vaccination series at weeks 0–2 with booster dose at week 34 (booster vax). Additionally, 3-month-old BALB/c mice were enrolled in the study at week 32 and received the following treatments: mock PBS injection (naive); and primary vaccination series at weeks 32–34 (recent vax). N = 20 per group at enrollment. Serum samples were collected at week 36. Splenocytes were collected at week 36 from N = 4–7 mice per group. Mice were challenged with SARS-CoV-2 Omicron strain at week 38 (N = 5–9 per group). The graphics were created with BioRender.com.
